Vectorite Biomedica Inc. was established in December 2004. In 2005, it has acquired technology rights of the lentiviral vectors from the Singapore-based INNOVA SCIENCE PTE. LTD. The company primarily engages in the research and development of immunotherapy technologies such as genetically modified autologous dendritic cells. Subsequently the company also won exclusive rights from the University of Florida on the siRNA technologies in 2006, which is crucial to the development of treatments for leukimia. At the current stage, the company's immunotechnology is mainly focused on the following three areas: 1)infectious diseases, 2) carcinoma; 3) stem cell and gene therapy.
Headquarters
6F-11, No.97,Sec.1 Xizhi Dist
Taipei City; Taipei City;
Contact Details: Purchase the Vectorite Biomedical Inc. report to view the information.
Website: http://www.vectorite.com.tw
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service